Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02179671
Title Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Recruitment Completed
Gender
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications
Therapies
Age Groups:
Covered Countries USA

Facility Status City State Zip Country Details
Research Site Goodyear Arizona 85338 United States Details
Research Site Washington District of Columbia 20007 United States Details
Research Site Augusta Georgia 30912 United States Details
Research Site Marietta Georgia 30060 United States Details
Research Site Ashland Kentucky 41101 United States Details
Research Site Saint Louis Missouri 63110 United States Details
Research Site Mineola New York 11501 United States Details
Research Site Huntersville North Carolina 28078 United States Details
Research Site Spokane Washington 99208-1129 United States Details
Research Site Tacoma Washington 98405 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field